Systemic treatment of hepatocellular carcinoma: An EASL position paper
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationReporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Self-citationKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationBruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Self-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Self-citationYau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Self-citationRen, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationImmune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Dolladille, C., Ederhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., Fedrizzi, S., Chrétien, B., Da-Silva, A., Plane, A.-F., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0726 · Cited by 587
Clinical states of cirrhosis and competing risks
D'Amico, G., Morabito, A., D'Amico, M., Pasta, L., Malizia, G., Rebora, P., & Valsecchi, M. G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.020 · Cited by 536
Novel patterns of response under immunotherapy
Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P., & Le Tourneau, C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 514
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
Choueiri, T. K., Schutz, F. A. B., Je, Y., Rosenberg, J. E., & Bellmunt, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2757 · Cited by 434
Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426
Self-citationAtkinson, T. M., Ryan, S. J., Bennett, A. V., Stover, A. M., Saracino, R. M., Rogak, L. J., Jewell, S. T., Matsoukas, K., Li, Y., & Basch, E. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3297-9 · Cited by 370
Finn, R. S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Self-citationFinn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V. V., Merle, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.267 · Cited by 319
Self-citationBiomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309
Self-citationAssessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0462 · Cited by 300
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Self-citationJe, Y., Schutz, F. A., & Choueiri, T. K. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70222-0 · Cited by 280
Reig, M., Rimola, J., Torres, F., Darnell, A., Rodriguez-Lope, C., Forner, A., LLarch, N., Ríos, J., Ayuso, C., & Bruix, J. (2013) · Hepatology · doi:10.1002/hep.26586 · Cited by 257
Self-citationThe effect of measuring error on the results of therapeutic trials in advanced cancer
Moertel, C. G., & Hanley, J. A. (1976) · Cancer · doi:10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a · Cited by 257
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., LLarch, N., Rimola, J., Darnell, A., Ríos, J., Ayuso, C., & Bruix, J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.030 · Cited by 228
Self-citationRimassa, L., Danesi, R., Pressiani, T., & Merle, P. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.004 · Cited by 228
Self-citationLencioni, R., Montal, R., Torres, F., Park, J.-W., Decaens, T., Raoul, J.-L., Kudo, M., Chang, C., Ríos, J., Boige, V., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.012 · Cited by 224
Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Bruix, J., da Fonseca, L. G., & Reig, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0179-x · Cited by 220
Self-citationPersoneni, N., Bozzarelli, S., Pressiani, T., Rimassa, L., Tronconi, M. C., Sclafani, F., Carnaghi, C., Pedicini, V., Giordano, L., & Santoro, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.016 · Cited by 210
Self-citationHaslam, A., Hey, S. P., Gill, J., & Prasad, V. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.012 · Cited by 209
Miller, A. A., Murry, D. J., Owzar, K., Hollis, D. R., Kennedy, E. B., Abou-Alfa, G., Desai, A., Hwang, J., Villalona-Calero, M. A., Dees, E. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0931 · Cited by 206
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar-Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 204
Totzeck, M., Mincu, R. I., & Rassaf, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006278 · Cited by 192
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Kim, C. G., Kim, C., Yoon, S. E., Kim, K. H., Choi, S. J., Kang, B., Kim, H. R., Park, S.-H., Shin, E.-C., Kim, Y.-Y., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.010 · Cited by 185
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
Pinter, M., Sieghart, W., Graziadei, I., Vogel, W., Maieron, A., Königsberg, R., Weissmann, A., Kornek, G., Plank, C., & Peck-Radosavljevic, M. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0191 · Cited by 178
RECIST — learning from the past to build the future
Litière, S., Collette, S., de Vries, E. G. E., Seymour, L., & Bogaerts, J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.195 · Cited by 152
Wörns, M., Weinmann, A., Pfingst, K., Schulte-Sasse, C., Messow, C., Schulze‐Bergkamen, H., Teufel, A., Schuchmann, M., Kanzler, S., Düber, C., et al. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31818ddfc6 · Cited by 149
Self-citationReig, M., Darnell, A., Forner, A., Rimola, J., Ayuso, C., & Bruix, J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394143 · Cited by 149
Self-citationLocal and Regional Therapies for Hepatocellular Carcinoma
Kloeckner, R., Galle, P. R., & Bruix, J. (2020) · Hepatology · doi:10.1002/hep.31424 · Cited by 139
Self-citationSystemic treatment of HCC in special populations
Rimassa, L., Personeni, N., Czauderna, C., Foerster, F., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.026 · Cited by 138
Self-citationWhen Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Oxnard, G. R., Morris, M. J., Hodi, F. S., Baker, L. H., Kris, M. G., Venook, A. P., & Schwartz, L. H. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs353 · Cited by 129
Use of checkpoint inhibitors in liver transplant recipients
Munker, S., & Toni, E. N. D. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618774631 · Cited by 112
Yau, T., Zagonel, V., Santoro, A., Acosta-Rivera, M., Choo, S. P., Matilla, A., He, A. R., Cubillo Gracián, A., El-Khoueiry, A. B., Sangro, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.478 · Cited by 110
Self-citationKambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 106
Kudo, M., Matilla, A., Santoro, A., Melero, I., Gracian, A. C., Acosta-Rivera, M., Choo, S. P., El-Khoueiry, A. B., Kuromatsu, R., El-Rayes, B. F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.327 · Cited by 99
Self-citationIavarone, M. A., Invernizzi, F., Czauderna, C., Sanduzzi‐Zamparelli, M., Bhoori, S., Amaddeo, G., Manini, M. A., López, M. F., Anders, M., Pinter, M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15551 · Cited by 99
Self-citationPoynard, T., Lebrec, D., Hillon, P., Sayegh, R., Bernuau, J., Naveau, S., Chaput, J., Klepping, C., RUEFF, B., & Benhamou, J. (1987) · Hepatology · doi:10.1002/hep.1840070306 · Cited by 97
Kelley, R. K., Ryoo, B., Merle, P., Park, J., Bolondi, L., Chan, S. L., Lim, H.-Y., Baron, A. D., Parnis, F. X., Knox, J. J., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000714 · Cited by 92
Self-citationKelley, R. K., Meyer, T., Rimassa, L., Merle, P., Park, J., Yau, T. C. C., Chan, S. L., Blanc, J., Tam, V. C., Tran, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3884 · Cited by 90
Self-citationCooper, K. L., Tappenden, P., Cantrell, A. J., & Ennis, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01050-w · Cited by 89
Alsina, A. E., Kudo, M., Vogel, A., Cheng, A., Tak, W. Y., Ryoo, B., Evans, T. R. J., López, C., Daniele, B., Misir, S., et al. (2019) · Liver Cancer · doi:10.1159/000504624 · Cited by 81
Zhu, A. X., Finn, R. S., Kang, Y., Yen, C.-J., Galle, P. R., Llovet, J. M., Assénat, E., Brandi, G., Motomura, K., Ohno, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01260-w · Cited by 71
Self-citationNie, R., Chen, F., Yuan, S., Luo, Y.-S., Chen, S., Chen, Y., Chen, X., Chen, Y.-B., Li, Y., & Zhou, Z. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.011 · Cited by 63
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Kelley, R. K., Mollon, P., Blanc, J., Daniele, B., Yau, T. C. C., Cheng, A., Valcheva, V., Marteau, F., Guerra, I., & Abou‐Alfa, G. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01378-y · Cited by 59
Mancuso, A., Mazzola, A., Cabibbo, G., Perricone, G., Enea, M., Galvano, A., Zavaglia, C., Belli, L. S., & Cammà, C. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.01.001 · Cited by 58
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
Rimassa, L., & Wörns, M. (2020) · Liver International · doi:10.1111/liv.14533 · Cited by 54
Self-citationWhen Can Intermediate Outcomes Be Used as Surrogate Outcomes?
DeMets, D. L., Psaty, B. M., & Fleming, T. R. (2020) · JAMA · doi:10.1001/jama.2020.1176 · Cited by 50
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients
Berretta, M., Benedetto, F. D., Maso, L. D., Cacopardo, B. S., Nasti, G., Facchini, G., Bearz, A., Spina, M., Garlassi, E., Re, V. D., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835c032f · Cited by 46
Bruix, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.033 · Cited by 40
Self-citationPinato, D. J., Kaseb, A. O., Wang, Y., Saeed, A., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000726 · Cited by 38
Self-citationFoerster, F., Hoppe‐Lotichius, M., Vollmar, J., Marquardt, J. U., Weinmann, A., Wörns, M., Otto, G., Zimmermann, T., & Galle, P. R. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619840221 · Cited by 35
Self-citationPalmer, M., Regev, A., Lindor, K. D., Avigan, M., Dimick‐Santos, L., Treem, W. R., MARCINAK, J. F., Lewis, J. H., Anania, F. A., Seekins, D. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15579 · Cited by 34
Sung, M. W., Finn, R. S., Qin, S., Han, K., Ikeda, K., Cheng, A., Kudo, M., Tateishi, R., Ikeda, M., Breder, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.317 · Cited by 33
Rimola, J., da Fonseca, L. G., Sapena, V., Perelló, C., Guerrero, A. F., Torner, M., Pons, M., de la Torre‐Aláez, M., Márquez, L., Calleja, J. L., et al. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109484 · Cited by 28
Self-citationPattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
Reig, M., Galle, P. R., Kudo, M., Finn, R. S., Llovet, J. M., Metti, A. L., Schelman, W. R., Liang, K., Wang, C., Widau, R. C., et al. (2020) · Liver International · doi:10.1111/liv.14731 · Cited by 25
Self-citationDíaz‐González, Á., Sanduzzi‐Zamparelli, M., da Fonseca, L. G., Costanzo, G. G. D., Alves, R. C. P., Iavarone, M. A., Leal, C. R. G., Sacco, R., Matilla, A. M., Hernández‐Guerra, M., et al. (2020) · Liver International · doi:10.1111/liv.14436 · Cited by 19
Self-citationde la Torre‐Aláez, M., Jordán-Iborra, C., Gardini, A. C., Bilbao, J. I., Rodríguez‐Fraile, M., Sancho, L., D’Avola, D., Herrero, J. I., Iñarrairaegui, M., & Sangro, B. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02444-2 · Cited by 13
Self-citationVogel, A., Rimassa, L., Sun, H., Abou‐Alfa, G. K., El-Khoueiry, A. B., Pinato, D. J., Daigl, M., Alvarez, J. S., Orfanos, P., Leibfried, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4585 · Cited by 8
Self-citation
Cited by
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Self-citationVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Metadata
- Authors
- Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 75
- Issue
- 4
- Pages
- 960-974
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3180754516
- Cited by
- 380
- References
- 86
- FWCI
- 37.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.